Payment overview · 2025
General Payments
$404.77
19 reported records · 15 companies
Healthcare provider profile · identity verified
Tanureet Kaur Arora
Allopathic & Osteopathic Physicians|Hospitalist · ROCHESTER, NY · NPI 1912382201
Verified facts
What the public records show
CMS Open Payments records show Tanureet Kaur Arora received $404.77 in general payments during 2025 across 19 reported records.
Xeris Pharmaceuticals, Inc. accounted for 15.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synjardy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.86 | 15.3% | 3 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $42.50 | 10.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.06 | 10.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $38.45 | 9.5% | 2 | 2025 |
| Arteriocyte Medical Systems, Inc. | Unresolved — no canonical attribution shown | $29.39 | 7.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.75 | 6.1% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $22.59 | 5.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.09 | 5.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.14 | 5.0% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $18.66 | 4.6% | 1 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.13 | 4.5% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $17.74 | 4.4% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $17.02 | 4.2% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $16.57 | 4.1% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $13.82 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $362.27 | 18 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $42.50 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $42.06 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $39.89 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $38.45 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $38.45 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $38.45 | 2 | 2025 |
Source payment records
|
|||||
| Magellan Normalized: magellan |
Device | Arteriocyte Medical Systems, Inc. | $29.39 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $22.59 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $19.58 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| TRYNGOLZA Normalized: tryngolza |
Drug | Ionis Pharmaceuticals, Inc. | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $13.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
102 | 30 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
160 | 42 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 532 | 142 |
| Metformin Hcl | Metformin Hcl | 292 | 78 |
| Metformin Hcl Er | Metformin Hcl | 271 | 87 |
| Trulicity | Dulaglutide | 224 | 56 |
| Pioglitazone Hcl | Pioglitazone Hcl | 216 | 59 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 201 | 76 |
| Jardiance | Empagliflozin | 160 | 42 |
| Glipizide | Glipizide | 138 | 49 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 133 | 52 |
| Glimepiride | Glimepiride | 128 | 39 |
| Ozempic | Semaglutide | 112 | 31 |
| Mounjaro | Tirzepatide | 106 | 25 |
| Atorvastatin Calcium | Atorvastatin Calcium | 104 | 33 |
| Synthroid | Levothyroxine Sodium | 102 | 30 |
| Januvia | Sitagliptin Phosphate | 87 | 26 |
| Glipizide Er | Glipizide | 84 | 22 |
| Humalog Kwikpen U-100 | Insulin Lispro | 83 | 30 |
| Humalog | Insulin Lispro | 78 | 28 |
| Novolog Flexpen | Insulin Aspart | 66 | 21 |
| Simvastatin | Simvastatin | 66 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 65 | 23 |
| Lisinopril | Lisinopril | 64 | 18 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 55 | 19 |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 54 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 46 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 44 | 19 |
| Methimazole | Methimazole | 40 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 37 | 15 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 35 | 14 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 35 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 35 | 12 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Losartan Potassium | Losartan Potassium | 33 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 32 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 30 | 13 |
| Gabapentin | Gabapentin | 28 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 23 | 11 |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 19 | suppressed |
| Testosterone | Testosterone | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Unifine Pentips Plus | Pen Needle, Diabetic | 14 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Gvoke Hypopen 1-Pack | Glucagon | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $404.77 · 19 records | Xeris Pharmaceuticals, Inc. | AFREZZA, CAPVAXIVE, CRENESSITY, CRYSVITA, Dexcom G6 Transmitter, EVENITY, GARDASIL 9, GVOKE HYPOPEN, Heplisav-B, ISTURISA, Magellan, OFEV, PROQUAD, RECORLEV, ROTATEQ, TRYNGOLZA, TWIIST, UBRELVY, VAXELIS, VAXNEUVANCE, Yorvipath | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error